World’s fastest Antibiotic Susceptibility Testing Platform

Antibiotic treatments are often preemptively initiated without knowing the antibiotic resistance profile of the causative pathogen. This leads to potentially inappropriate therapies. Ultra-rapid Antibiotic Susceptibility Testing (AST) is key in identifying the effective antibiotics, and here are compelling reasons for healthcare providers to prioritize it.

Antibiotic resistance changes treatable infections into significant health threats. Along with the clinical challenges comes an extra financial load, as antibiotic resistance typically adds around $1,400 to the hospital bill for treating bacterial infections, according to the CDC in the US. This steep rise indicates a concerning trend where healthcare costs climb hand-in-hand with the complexity of treating resistant strains.

Resistell, an EPFL spin-off developing rapid phenotypic antibiotic susceptibility testing (AST) solutions, announces the peer-reviewed article in the Nature Communications journal. The publication marks the completion of the company’s technology validation stage and showcases the potential of the Resistell nanomotion technology platform as a diagnostic in the fight against antimicrobial resistance (AMR).

With a remarkable 25-year journey at the forefront of healthcare innovation, Trevor brings a wealth of experience from his leadership roles across research, clinical, and corporate spheres globally. His track record of innovation, coupled with a profound understanding of the healthcare industry’s challenges and opportunities, makes him an invaluable addition to our team. Welcome aboard, Trevor!

Cellectric, Resistell and Lausanne University Hospital will collaborate on a joint Eurostars project to build Phenotech-CF, a workflow that will reshape how antimicrobials are delivered to patients suffering from cystic fibrosis.

Our latest webcast with Nature is now available for replay. Join us as we delve into the science behind nanomotion technology and its application in real-world healthcare settings. Learn about Resistell’s groundbreaking technology platform that leverages the power of nanomotion technology to transform the fight against antibiotic resistance.

TOP 100 Swiss Startup Award has become a benchmark in Switzerland’s startup ecosystem. The award show connects the most promising Swiss startups with Swiss and international investors, executives, and journalists. The invitation-only Award Night has become the most awaited start-up event of the year. We are honored to announce that Resistell has once again secured a coveted spot in the Top 10 of the TOP 100 Swiss Startup Award! For the third time, our dedication to innovation has been recognized by a panel of 100 leading investors and industry experts. This prestigious award is not just a recognition of our hard work, but also a testament to the incredible team behind Resistell and the invaluable support from our partners and stakeholders. We are thrilled to be part of Switzerland’s dynamic startup ecosystem, and we remain committed to pushing the boundaries of science and technology to combat antibiotic resistance and improve patient care.

Scientists from EPFL and Vrije Universiteit Brussel have been working for several years on a new nanomotion based method to detect bacterial sensitivity to antibiotics. In essence, it involves “watching the bacteria dance”. Joining Stéphane Gabioud and journalist, Cécile Guérin, on Swiss radio show CQFD to discuss this new method is Professor Gilbert Greub MD-PhD, Chief Physician of Diagnostic Laboratories at the University Hospital of Vaud (CHUV) and scientific advisor to Resistell, the company commercializing this novel detection method.

The @Innovative Medicines for Tuberculosis (iM4TB) foundation, a Swiss non-profit fighting tuberculosis (TB), is pleased to announce a new partnership with @Resistell. The partners will harness Resistell’s proprietary Phenotech technology to further investigate iM4TB’s TB drug candidate, macozinone (PBTZ169).

Resistell, a leader in phenotypic nanomotion technology for measuring living cells, is proud to announce the launch of its next international, multisite clinical study, PHENOTECH-1.